Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT05611931. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v 1.1\]) after completing at least 12 weeks of platinum-based therapy. A total of 276 participants will be enrolled in the study and randomized in a 1:1 ratio to maintenance therapy with either selinexor or placebo.
Study identification
- NCT ID
- NCT05611931
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 257 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 18, 2023 (Actual)
- Primary completion
- May 22, 2026 (Actual)
- Completion
- Jan 2028 (Estimated)
- Last update posted
- Oct 29, 2026
2023 – 2028
United States locations
- U.S. sites
- 65
- U.S. states
- 29
- U.S. cities
- 58
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The University of Alabama at Birmingham | Birmingham | Alabama | 35205 | — |
| Honor Health | Phoenix | Arizona | 85016 | — |
| University of Arkansas for Medical Sciences | Little Rock | Arkansas | 72205 | — |
| UC DAVIS | Davis | California | 95616 | — |
| City of Hope National Medical Center | Duarte | California | 91010 | — |
| City of Hope at Irvine Lennar | Irvine | California | 92618 | — |
| Cancer and Blood Specialty Clinic | Los Alamitos | California | 90720 | — |
| UCLA - Women's Health Clinical Research Unit | Los Angeles | California | 90095 | — |
| Long Beach Memorial Medical Center | Los Angeles | California | 90806 | — |
| Stanford University | Palo Alto | California | 94304 | — |
| California Pacific Medical Center | San Francisco | California | 94109 | — |
| Broward Health Medical Center | Fort Lauderdale | Florida | 33316 | — |
| Mount Sinai Comprehensive Cancer Center | Miami Beach | Florida | 33140 | — |
| Advent Health | Orlando | Florida | 32804 | — |
| Grady Hospital | Atlanta | Georgia | 30303 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| Georgia Cancer Center at Augusta University | Augusta | Georgia | 30912 | — |
| Illinois Cancer Specialists | Arlington Heights | Illinois | 60005 | — |
| NorthShore University Health System | Evanston | Illinois | 60201 | — |
| Northwest Cancer Center | Dyer | Indiana | 46311 | — |
| Goshen Health | Goshen | Indiana | 46526 | — |
| St Vincent Hospital | Indianapolis | Indiana | 46260 | — |
| University of Iowa | Iowa City | Iowa | 52242 | — |
| LSU Health Sciences Center New Orleans | New Orleans | Louisiana | 70119 | — |
| Tufts Medical Center | Boston | Massachusetts | 02111 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| USON - Minnesota Oncology Hematology | Minneapolis | Minnesota | 55404 | — |
| University of Minnesota | Minneapolis | Minnesota | 55455 | — |
| St. Dominic's Gynecologic Oncology | Jackson | Mississippi | 39216 | — |
| Midwest Ventures Group HCA MId America Division | Kansas City | Missouri | 64132 | — |
| Intermountain Health St. Vincent Regional Hospital | Billings | Montana | 59101 | — |
| Center Of Hope | Reno | Nevada | 89511 | — |
| Women's Cancer Care Associates, LLC | Albany | New York | 12208 | — |
| NYU Langone Hospital-Long Island | Mineola | New York | 11501 | — |
| Northwell Health - Zuckerberg Cancer Center | New Hyde Park | New York | 11042 | — |
| Perlmutter Cancer Center at NYU Langone Health | New York | New York | 10016 | — |
| Lenox Hill Hospital | New York | New York | 10075 | — |
| Northwell Health - Queens Cancer Center | Rego Park | New York | 11374 | — |
| University of Rochester | Rochester | New York | 14642 | — |
| Atrium Health Levine Cancer Institute | Charlotte | North Carolina | 28209 | — |
| Duke Cancer Center | Durham | North Carolina | 27710 | — |
| MetroHealth | Cleveland | Ohio | 44109 | — |
| Zangmeister Cancer Center | Columbus | Ohio | 43219 | — |
| ProMedica Flower Hospital | Sylvania | Ohio | 43560 | — |
| University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | 73104 | — |
| Oklahoma Cancer Specialists and Research Institute, LLC | Tulsa | Oklahoma | 74146 | — |
| Oncology Associates of Oregon | Eugene | Oregon | 97401 | — |
| Providence Portland Medical Center | Portland | Oregon | 97213 | — |
| Alliance Cancer Specialists | Langhorne | Pennsylvania | 19047 | — |
| Magee - Women's Hospital | Pittsburgh | Pennsylvania | 15213 | — |
| Allegheny Health Network - West Penn Hospital | Pittsburgh | Pennsylvania | 15224 | — |
| Avera | Sioux Falls | South Dakota | 57105 | — |
| University of Tennessee Medical Center | Knoxville | Tennessee | 37920 | — |
| University of Tennessee Health Science Center | Memphis | Tennessee | 38103 | — |
| USON - Texas Oncology, Austin Central | Austin | Texas | 78731 | — |
| Parkland Health & Hospital System | Dallas | Texas | 75235 | — |
| Texas Oncology - Dallas | Dallas | Texas | 75246 | — |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | — |
| Houston Methodist | Houston | Texas | 77030 | — |
| Texas Oncology - San Antonio | San Antonio | Texas | 78240 | — |
| Texas Oncology - The Woodlands | The Woodlands | Texas | 77380 | — |
| Texas Oncology, PC, Tyler | Tyler | Texas | 75702 | — |
| University of Utah | Salt Lake City | Utah | 84112 | — |
| University of Virginia | Charlottesville | Virginia | 22908 | — |
| University of Wisconsin Hospital and Clinics | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 120 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05611931, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 29, 2026 · Synced Nov 13, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.